Company Presentation

Osasuna Therapeutics SA

Category:Emerging Biotech Company
Date:April 23, 2024
Time:13:30 – 13:45
Speaker:Mark de Boer, CEO

Company profile

Osasuna, founded in 2022, based on the work by Prof. Kroemer at Sorbonne University, Paris. Starvation of cells causes the autophagy-dependent cellular release of ACBP/DBI and and consequent feedback inhibition of autophagy. Plasma ACBP/DBI is elevated in various pathologies and neutralization of ACBP/DBI with mAbs induces autophagy, protects diverse organs against physical/chemical damage, mediates senolysis, inhibits inflammation and improves cancer immunosurveilance.

Further information